Go to main content


The latest news
Updates on GC Pharma’s
Journey of supporting
Health and happiness.

소식 상세 테이블 표
Title GC Pharma Reports Q1 2021 Results
Date of registration 2021-04-28
Attachment File
YONGIN, South Korea, 28 April 2021 - GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 31 March 2021.

First-Quarter Reported Results(1)

Key Figures

Q1 2020


Total revenues

KRW 282.2 billion


Operating profit

KRW 5.0 billion


K-IFRS profit after taxation

KRW 17.5 billion


(1) Results from continuing operations (Green Cross MS’ blood bag business has been classified as discontinued operations) 

(2) Results and percentages compare to equivalent 2020 period   

Financial Highlights
Delivered total revenue decline of 8.3% KRW 282.2 billion (2019 Q1: 307.8 billion), and operating profit decreased 18.0% to KRW 5.0 billion (2020 Q1: 6.1 billion) in the first quarter. 

Unconsolidated revenues temporal setback due to termination of in-licence product distribution and vaccine’s international shipping schedule changes

● Maintain double-digit growth in consolidated subsidiaries, including Green Cross MS, Green Cross LabCell and Green Cross Wellbeing

● S/H Flu Vx sales to be reflected in the second quarter unlike prior year, Vx sales expected to be stronger in second half of the year

● Int. sales of Hunterase sales up 412%, as its initial performance in Japan and China was reflected

● In spite of gross margin profit growth 4%p driven by COGs improvement, operating profit impacted by SG&A+R&D cost maintain prior year level

About GC Pharma
GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name.

This release includes forward-looking statements, which express the current beliefs and expectations of GC Pharma’s management. Such statements speak only as of the date on which they are made and the company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


List view


GC녹십자는 이메일 수집을 거부합니다

본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 이메일 주소를 수집하는 행위를 거부하며,
이를 위반시 정보통신망 이용촉진 및 정보보호 등에 관한 법률에 의해 형사처벌됨을
유념하시기 바랍니다

게시일: 2003년 9월 1일